Using iron-based phosphate binders in phosphate reduction and anemia improvement in patients receiving dialysis: a meta-analysis of randomized controlled trials
出版年份 2021 全文链接
标题
Using iron-based phosphate binders in phosphate reduction and anemia improvement in patients receiving dialysis: a meta-analysis of randomized controlled trials
作者
关键词
-
出版物
INTERNATIONAL UROLOGY AND NEPHROLOGY
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2021-03-06
DOI
10.1007/s11255-021-02820-y
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Randomised clinical trial of ferric citrate hydrate on anaemia management in haemodialysis patients with hyperphosphataemia: ASTRIO study
- (2019) Keitaro Yokoyama et al. Scientific Reports
- Ferric Citrate Decreases Fibroblast Growth Factor 23 and Improves Erythropoietin Responsiveness in Hemodialysis Patients
- (2018) Noriaki Maruyama et al. AMERICAN JOURNAL OF NEPHROLOGY
- Current and potential treatment options for hyperphosphatemia
- (2018) Fabio Carfagna et al. Expert Opinion On Drug Safety
- Long-term efficacy and safety of sucroferric oxyhydroxide in African American dialysis patients
- (2018) Stuart M. Sprague et al. Hemodialysis International
- Impact of Inflammation on Ferritin, Hepcidin and the Management of Iron Deficiency Anemia in Chronic Kidney Disease
- (2018) Norishi Ueda et al. Nutrients
- Efficacy and safety of sucroferric oxyhydroxide compared with sevelamer hydrochloride in Japanese haemodialysis patients with hyperphosphataemia: A randomized, open-label, multicentre, 12-week phase III study
- (2017) Fumihiko Koiwa et al. NEPHROLOGY
- Renal association clinical practice guideline on Anaemia of Chronic Kidney Disease
- (2017) Ashraf Mikhail et al. BMC Nephrology
- Dose–response efficacy and safety of PA21 in Japanese hemodialysis patients with hyperphosphatemia: a randomized, placebo-controlled, double-blind, Phase II study
- (2016) Fumihiko Koiwa et al. Clinical and Experimental Nephrology
- The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial
- (2015) Peter N. Van Buren et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- A 12-Week, Double-Blind, Placebo-Controlled Trial of Ferric Citrate for the Treatment of Iron Deficiency Anemia and Reduction of Serum Phosphate in Patients With CKD Stages 3-5
- (2015) Geoffrey A. Block et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Sucroferric Oxyhydroxide: A Review in Hyperphosphataemia in Chronic Kidney Disease Patients Undergoing Dialysis
- (2015) Sarah L. Greig et al. DRUGS
- Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients
- (2015) J. Floege et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Effect of oral ferric citrate on serum phosphorus in hemodialysis patients: multicenter, randomized, double-blind, placebo-controlled study
- (2014) Chien-Te Lee et al. JOURNAL OF NEPHROLOGY
- Ferric Citrate Controls Phosphorus and Delivers Iron in Patients on Dialysis
- (2014) J. B. Lewis et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients
- (2014) Jürgen Floege et al. KIDNEY INTERNATIONAL
- Gastrointestinal symptoms: A comparison between patients undergoing peritoneal dialysis and hemodialysis
- (2014) Rui Dong WORLD JOURNAL OF GASTROENTEROLOGY
- Ferric citrate spans mineral metabolism and anemia domains in ESRD: a review of efficacy and safety data
- (2014) Marvin Sinsakul et al. Expert Review of Clinical Pharmacology
- Efficacy and safety of SBR759, a novel calcium-free, iron (III)-based phosphate binder, versus placebo in chronic kidney disease stage V Japanese patients on maintenance renal replacement therapy
- (2013) Masafumi Fukagawa et al. Clinical and Experimental Nephrology
- A randomized trial of JTT-751 versus sevelamer hydrochloride in patients on hemodialysis
- (2013) K. Yokoyama et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Effect of Oral JTT-751 (Ferric Citrate) on Hyperphosphatemia in Hemodialysis Patients: Results of a Randomized, Double-Blind, Placebo-Controlled Trial
- (2012) Keitaro Yokoyama et al. AMERICAN JOURNAL OF NEPHROLOGY
- Randomized Clinical Trial of the Iron-Based Phosphate Binder PA21 in Hemodialysis Patients
- (2012) R. P. Wuthrich et al. Clinical Journal of the American Society of Nephrology
- Efficacy and safety of SBR759, a novel calcium-free, iron(III)-based phosphate binder, in Asian patients undergoing hemodialysis: A 12-week, randomized, open-label, dose-titration study versus sevelamer hydrochloride
- (2011) JIN-BOR CHEN et al. NEPHROLOGY
- Efficacy and safety of SBR759, a new iron-based phosphate binder
- (2010) Geoffrey A. Block et al. KIDNEY INTERNATIONAL
- Iron-Magnesium Hydroxycarbonate (Fermagate): A Novel Non-Calcium-Containing Phosphate Binder for the Treatment of Hyperphosphatemia in Chronic Hemodialysis Patients
- (2009) C. W. McIntyre et al. Clinical Journal of the American Society of Nephrology
- Lanthanum Carbonate Effectively Controls Serum Phosphate Without Affecting Serum Calcium Levels in Patients Undergoing Hemodialysis
- (2008) Takashi Shigematsu et al. THERAPEUTIC APHERESIS AND DIALYSIS
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started